Related coverage linked through entity extraction aliases.
Jul 01, 2026
Supreme Court unanimously reversed the Federal Circuit in Hikma v. Amarin, ruling that 'skinny label' generic marketing does not induce patent infringement absent active steps to encourage it. The decision requires affirmative conduct, not mere plausible interpretations, to support inducement claims.
Jul 13, 2026
The Supreme Court unanimously held in Hikma v. Amarin that induced infringement requires affirmative steps, not foreseeable or passive statements. The ruling raises the pleading bar for brand owners and extends beyond pharmaceutical skinny labels.
Apr 24, 2026
Two retrospective studies in type 2 diabetes patients with unruptured intracranial aneurysms linked GLP-1RAs to lower non-traumatic subarachnoid haemorrhage risk. One study also showed lower all-cause mortality over five years.
Feb 26, 2026
Eli Lilly's oral GLP-1 drug orforglipron demonstrated 6-8% weight loss in type 2 diabetes patients compared to 4-5% with oral semaglutide in a phase 3 trial, though discontinuation rates were higher due to gastrointestinal side effects.
Feb 16, 2026
Three comprehensive reports examine the monoclonal antibody landscape, covering CD47-targeted immunotherapy pipelines, competitive analysis of 180+ companies developing mAb therapeutics, and recombinant antibody market forecasts through 2033.
